• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amyris, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    7/27/21 5:08:43 PM ET
    $AMRS
    Major Chemicals
    Industrials
    Get the next $AMRS alert in real time by email
    amrs-20210726
    8-K0001365916FALSE00013659162021-07-262021-07-26

     
     
     
     UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
       
     
     
    FORM 8-K
    Current Report Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    ____________________


    Date of report (Date of earliest event reported): July 26, 2021
     
    Amyris, Inc.
    (Exact name of registrant as specified in its charter)
     
    Delaware001-3488555-0856151
    (State or other jurisdiction
    of incorporation)
    (Commission File Number)
    (I.R.S. Employer
    Identification No.)
     
     
    5885 Hollis Street, Suite 100, Emeryville, CA94608    
    (Address of Principal Executive Offices) (Zip Code)
     
     
     (510)450-0761 
     (Registrant’s telephone number, including area code)
       
     (Former name or former address, if changed since last report.) 

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):



    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
      Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.0001 par value per shareAMRSThe Nasdaq Stock Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On July 26, 2021, Amyris, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) for the following purposes:

    1.To approve the issuance to John Melo, the Company’s President and Chief Executive Officer (“CEO”), of (x) a performance-vesting restricted stock unit award (the “CEO PSU”) representing the right to receive up to 6,000,000 shares of the Company’s common stock under the 2020 Equity Incentive Plan (the “2020 Plan”) based on the achievement of four specified stock price performance metrics over a four-year period and (y) a one-time waiver of the annual per-person award limit under the 2020 Plan of 4,000,000 shares with respect to the CEO PSU and all other awards representing the right to receive shares of the Company’s common stock under the 2020 Plan that may be granted to the CEO in calendar year 2021 (“Proposal 1”);

    2.To approve an amendment of the 2020 Plan to increase the number of shares authorized for issuance by 2,750,000 shares (“Proposal 2”); and

    3.To act upon such other matters as may properly come before the Special Meeting or any adjournments or postponements thereof.

    Proposal 1 was approved by the following vote:
    ForAgainstAbstainBroker Non-Vote
    104,403,91267,789,00512,550,630—

    Proposal 2 was approved by the following vote:

    ForAgainstAbstainBroker Non-Vote
    104,481,64267,825,34112,436,563—

    No further business was brought before the Special Meeting.




    Item 9.01 Financial Statements and Exhibits

    (d) Exhibits
    The following exhibits are furnished herewith:

    Exhibit NumberDescription
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)





    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
      AMYRIS, INC. 
        
        
    Date: July 27, 2021By: /s/ Nicole Kelsey 
      Nicole Kelsey 
      General Counsel and Secretary

    Get the next $AMRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRS

    DatePrice TargetRatingAnalyst
    5/18/2023$3.10 → $0.65Buy → Hold
    Jefferies
    5/10/2023$4.00 → $1.25Outperform → Market Perform
    TD Cowen
    4/28/2023$1.50Buy
    Canaccord Genuity
    11/10/2022Overweight → Neutral
    JP Morgan
    11/9/2022Outperform → Perform
    Oppenheimer
    8/10/2022$4.00 → $2.00Buy → Neutral
    ROTH Capital
    6/24/2022Neutral
    JP Morgan
    5/25/2022$2.50Neutral
    Piper Sandler
    More analyst ratings

    $AMRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amyris downgraded by Jefferies with a new price target

      Jefferies downgraded Amyris from Buy to Hold and set a new price target of $0.65 from $3.10 previously

      5/18/23 7:22:16 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Amyris downgraded by TD Cowen with a new price target

      TD Cowen downgraded Amyris from Outperform to Market Perform and set a new price target of $1.25 from $4.00 previously

      5/10/23 7:29:32 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Canaccord Genuity initiated coverage on Amyris with a new price target

      Canaccord Genuity initiated coverage of Amyris with a rating of Buy and set a new price target of $1.50

      4/28/23 7:13:42 AM ET
      $AMRS
      Major Chemicals
      Industrials